SEHK:1093
SEHK:1093Pharmaceuticals

How FDA-Approved Trials for Obesity and Depression Therapies Will Impact CSPC Pharmaceutical Group (SEHK:1093) Investors

Earlier this month, CSPC Pharmaceutical Group reported that it had received U.S. FDA approval to begin clinical trials for two innovative candidates: SYH2069, a GLP-1/GIP dual-biased agonist injection for obesity and overweight patients with comorbidities, and SYH2056, a selective 5-HT2A receptor agonist tablet for major depressive disorder. By advancing a next-generation obesity therapy and a potentially best-in-class antidepressant into U.S. and China trials, CSPC is expanding its presence...
SEHK:175
SEHK:175Auto

Does Geely Still Offer Value After Recent Volatility in China’s EV Market?

Wondering if Geely Automobile Holdings is actually good value at today’s price, or if the market has already driven off with the easy gains? This breakdown is designed to give you a clear, no-jargon answer. Despite a choppy ride in the short term, with the share price down 6.3% over the last week and 3.7% over the last month, the stock is still up 17.6% year to date and 7.6% over the last year. It has delivered 52.9% over three years but lost 23.0% across five years. Recent headlines around...
SEHK:2883
SEHK:2883Energy Services

Did SSE 180 Removal Just Shift China Oilfield Services' (SEHK:2883) Investment Narrative?

On 12 December 2025, China Oilfield Services Limited was removed from the SSE 180 Index, ending its inclusion in one of Shanghai’s core equity benchmarks. This index exit can prompt mechanical selling by index-tracking funds and may influence how investors view the company’s role in China’s oilfield services sector. We’ll now examine how China Oilfield Services’ removal from the SSE 180 Index could reshape its investment narrative and future positioning. Trump's oil boom is here - pipelines...